<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6451">
  <stage>Registered</stage>
  <submitdate>18/04/2017</submitdate>
  <approvaldate>18/04/2017</approvaldate>
  <nctid>NCT03136185</nctid>
  <trial_identification>
    <studytitle>IMG-7289 in Patients With Myelofibrosis</studytitle>
    <scientifictitle>A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IMG-7289-CTP-102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myelofibrosis</healthcondition>
    <healthcondition>Post-polycythemia Vera Myelofibrosis (PPV-MF)</healthcondition>
    <healthcondition>Post-essential Thrombocythemia Myelofibrosis (PET-MF)</healthcondition>
    <healthcondition>Primary Myelofibrosis (PMF)</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IMG-7289

Experimental: IMG-7289 - Single starting dose with individualized dose titrations throughout


Treatment: drugs: IMG-7289
Differentiation therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of treatment-emergent adverse events, and changes in physical examination, vital signs and laboratory parameters [safety and tolerability] - as measured by the frequent monitoring of: adverse events, physical examination and vital signs and laboratory parameters.</outcome>
      <timepoint>Assessed from the time of first dose through 28 days after end of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Drug Concentration - as measured by Cmin sampling.</outcome>
      <timepoint>Up to 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Spleen Volume - Reduction in spleen volume based on MRI (or CT)</outcome>
      <timepoint>Baseline to each visit where the variable is measured.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  &gt;18 years

          -  Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for
             myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT

          -  High or intermediate-2 risk disease, as defined per protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Receiving other treatments for the condition (with exceptions and time limits)

          -  Major surgery in last 4 weeks, minor surgery in the last 2 weeks

          -  History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of
             Screening

          -  History of splenectomy

          -  Current use of prohibited medications

          -  A concurrent second active and nonstable malignancy

          -  Known HIV infection or active Hepatitis B or Hepatitis C virus infection

          -  Other hematologic/biochemistry requirements, as per protocol

          -  Use of investigational agent within last 14 days

          -  Pregnant or lactating females</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Imago BioSciences,Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 1 open label study of an orally administered LSD1 inhibitor, IMG-7289, in
      patients with myelofibrosis.

      This study investigates the following:

        -  The safety and tolerability of IMG-7289

        -  The pharmacokinetics of IMG-7289

        -  The pharmacodynamic effect of IMG-7289</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03136185</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Ross</name>
      <address>Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Jennifer Peppe</name>
      <address />
      <phone>+1-415-529-5055</phone>
      <fax />
      <email>jennifer.peppe@imagobio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>